表紙
市場調查報告書

老年性黃斑部病變(AMD)/其他視網膜疾病治療藥物的全球市場(2019∼2029年):乾性/濕性AMD、糖尿病視網膜病變(DR)、Lucentis、Eylea、Avastin、Visudyne

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne

出版商 Visiongain Ltd 商品編碼 290418
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
老年性黃斑部病變(AMD)/其他視網膜疾病治療藥物的全球市場(2019∼2029年):乾性/濕性AMD、糖尿病視網膜病變(DR)、Lucentis、Eylea、Avastin、Visudyne Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne
出版日期: 2019年07月31日內容資訊: 英文 170 Pages
簡介

全球視網膜疾病治療藥物市場規模,預測在2018年會達到148億5000萬美元。另外,也預估到了2028年,會成長6.7%的CAGR(複合年均增長率)。

本報告調查了老年性黃斑部病變(AMD)等視網膜疾病的藥劑市場,並統整了銷售趨勢、技術趨勢、市場機會及收益預測、部門別(濕性AMD、乾性AMD、DR(糖尿病視網膜病變))的詳細趨勢等。

第1章 分析概要

第2章 全球老年性黃斑部病變(AMD)/其他視網膜疾病市場

  • 何謂視網膜疾病
  • 視網膜疾病的種類
  • AMD/其他視網膜疾病的診斷、治療方法
  • AMD的推估患者數
  • DR(糖尿病視網膜病變)的併發症患者數
  • RVO(視網膜靜脈阻塞)的推估患者數
  • 可預期的市場急速成長
  • Eylea成為最主要的治療藥物
  • Regeneron佔據重要地位
  • 最多此類病患的區域是哪?

第3章 視網膜疾病市場:領域別分析

  • 濕性AMD:現在最大的收益來源
  • 濕性AMD:因為由血管輸遞,所以藥劑標的變得明確
  • 乾性AMD:抑制/ 停止對視網膜色素上皮層(RPE)細胞的傷害的unmet needs
  • DR(糖尿病視網膜病變) :臨床上對於糖尿病引起之黃斑部水腫(DME)的關注提升
  • Lucentis:由於Eylea的延長實驗,發現在其他領域的可能性
  • 全領域的預測

第4章 AMD/其他視網膜疾病市場中已獲得認可的產品

  • 現在的產品未來也會獨佔市場嗎?
  • Lucentis:市場上第2名的治療藥物
  • Eylea:穩坐第一名嗎?
  • Avastin:沒獲得正式認可,卻是最常使用的產品
  • Visudyne (Valeant/Novartis): 在調查期間中預期銷售額會減少
  • 其他產品

第5章 用於濕性AMD的治療藥物研發產品

  • 主要的研發候補藥物
  • Fovista (Ophthotech Corporation/Novartis):會成為下一個焦點嗎?
  • 在研發線上的其他成長因子標的
  • APL-2:AMD相關的地圖狀萎縮(GA)患者的治療方法進步
  • 新的抗VEGFR劑或輸遞系統是否必要?
  • 為了活化抗發炎途徑而生的新的藥物輸遞系統
  • 開發濕性AMD治療藥物中正在分析的新標的
  • 再生醫療方法

第6章 乾性AMD市場的研發產品

  • 誰能在乾性AMD市場有飛躍性的成長?
  • MC-1101 (MacuCLEAR): 會成為市場領袖嗎?
  • ACU-4429 (Acucela):在臨床實驗第三相的Visual cycle modulator
  • 在乾性AMD的補體阻礙上備受期待
  • 皮質類固醇:因可作用在乾性AMD病因的發炎症狀上而成為標的
  • 神經防護作用:現代醫療的崇高目標之一
  • 再生醫療:乾性AMD是最大的疾病標的之一
  • 乾性AMD與其他治療方法

第7章 糖尿病視網膜病變症 (DR) 市場的研發產品

  • Ozurdex/Posurdex (Allergan):為了一般的DME患者而認可
  • Lucentis(樂舒晴):顛覆DR藥物市場?
  • 追加新的抗VEGF劑
  • 用於DR的開發中的類固醇
  • 用於DR的開發中的其他產品

第8章 地區市場分析

  • 哪個市場會獲得最大的成長可能性?
  • 美國:視網膜疾病主要市場
  • 日本:極具潛力的廣大市場
  • 歐洲主要5國 (EU5):因人口高齡化而促進市場成長
  • BRIC各國:最大的市場成長促進要素

第9章 全球的AMD/其他視網膜疾病藥物市場的主要企業

  • Novartis AG
    • 企業概要
    • 財務分析
    • 近年趨勢
  • F. Hoffmann-La Roche, Ltd.
  • Bayer AG
  • Regeneron Pharmaceuticals
  • Valent Pharmaceuticals International, Inc.
  • Pfizer Inc.
  • Acucela, Inc.
  • IVERIC bio, Inc.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Allergan PLC

第10章 產業、市場定性分析

  • 強項:在眼科市場最活潑的領域
  • 弱項:對於抗VEGF途徑的過度依賴
  • 機會:市場與研究開發 (R&D)的新的相乘效果
  • 威脅:對於乾性AMD或DR來說,比起預防、管理或藥物治療來得突出?
  • 社會性因素:低看診率、低服藥守規
  • 技術性因素:眼科相關創新
  • 經濟性因素:健保不給付的治療與償還治療費的問題
  • 政治性因素:人口結構與糖尿病的問題

第11章 結論

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0460

The global macular degeneration and other retinal diseases market is estimated at $14.85bn in 2018 and is expected to grow at a CAGR of 6.7% during the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 176-page report you will receive 110 charts - all unavailable elsewhere.

The 176-page report provides clear detailed insight into the macular degeneration (AMD) and other reginal diseases drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global AMD and Other Retinal Diseases Market forecasts from 2019-2029

Revenue forecasts for Global AMD and Other Retinal Diseases Drugs Market by Disease Segment from 2019-2029:

  • Wet AMD
  • Dry AMD
  • Diabetic Retinopathy
  • Other Retinal Diseases

Revenue forecasts for Global AMD and Other Retinal Diseases Drugs Market by Product from 2019-2029:

  • Lucentis
  • Eylea
  • Avastin
  • Visudyne
  • Others

Revenue forecasts for the Global AMD and Other Retinal Diseases Drugs Market by Region from 2019-2029:

  • U.S.
  • Japan
  • China
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Brazil
  • Russia
  • India
  • Rest of the World

Discussion and profiles of the below selected leading companies:

  • Acucela, Inc.
  • Allergan Plc
  • Bayer AG
  • F. Hoffman-La Roche, Ltd.
  • GlaxoSmithKline Pharmaceuticals, Ltd.
  • IVERIC bio, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals
  • Valent Pharmaceuticals International, Plc

Analysis of the Drivers, Restraints, Opportunities and Threats of the global AMD and other retinal diseases market

  • The report also includes a SWOT and STEP analysis of the global AMD and other retinal diseases market
  • Discussion on the pipeline for Wet AMD. Dry AMD and Diabetic Retinopathy

Key questions answered by this report:

  • How is the retinal diseases market evolving and what are the market prospects from 2018?
  • What forces stimulate and restrain that market?
  • What are the sales figures for retinal diseases?
  • How will revenues of retinal diseases segments grow over the forecast period, 2019 to 2029?
  • How will individual product sales develop to 2029?
  • Which R&D pipeline products are likely to dominate the market in the next ten years, and what are their sales potentials?
  • Which submarkets and national markets form the main drivers of the overall world market to 2029?
  • How will social, technological, economic and political forces influence regional markets and world-level submarkets?
  • How will market shares of top countries change by 2029 - with their revenues - and which regions will lead the market in 2029?
  • Who are the leading companies and what are their prospects over the forecasted period?

Visiongain's study is intended for anyone requiring commercial analyses for the macular degeneration (AMD) and other reginal diseases drugs market. You find data, trends and predictions.

Buy our report today Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. World AMD and Other Disease Market, 2018

  • 2.1 What are Retinal Diseases?
  • 2.2 Types of Retinal Diseases
  • 2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
  • 2.4 Nearly 200 Million People with AMD?
  • 2.5 Over 100 Million with DR
  • 2.6 First RVO Estimates Suggest Patient Population of 16 Million
  • 2.7 Market to Grow Rapidly by 2029
  • 2.8 Eylea Became Leading Drug in the Market
  • 2.9 Regeneron the Leading Presence in the Market
  • 2.10 Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2018

  • 3.1 Wet AMD Still the Main Source of Revenue in the Market
  • 3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
    • 3.2.1 Revenue Forecasting for Wet AMD segment, 2019-2029
  • 3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
    • 3.3.1 Dry AMD Segment to Emerge in the Forecast Period
  • 3.4 DR: Coming into Clinical Focus, with DME the Main Target
    • 3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
  • 3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
  • 3.6 Projections of all Segments, 2019-2029

4. Approved Products in the AMD and Other Retinal Diseases Market, 2019-2029

  • 4.1 Will the Current Products Dominate the Market through 2029?
  • 4.2 Lucentis: Second Leading Drug in the Market
    • 4.2.1 Positive Revenue Growth Shown in Past: 2014-2017
    • 4.2.2 Shadow of Avastin Still Hangs Over Lucentis
    • 4.2.3 Lucentis/Avastin Matters
    • 4.2.4 Eylea: The Bigger Threat to Lucentis?
    • 4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves into DME and Beyond
    • 4.2.6 Improving Cost and Compliance for Lucentis
    • 4.2.7 Lucentis Revenue Forecast 2019-2029
    • 4.2.8 Will Loss of Physician Goodwill Harm Lucentis' Growth?
  • 4.3 Eylea: Holds the Throne?
    • 4.3.1 Increasing Revenue Growth in Past: Outside the US Sale Amplified
    • 4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
    • 4.3.3 First Wave of Eylea's Expansion Finally Beginning to Break?
    • 4.3.4 Eylea into DME and Other New Indications
    • 4.3.5 Eylea Revenue Forecast 2019-2029
    • 4.3.6 How Far Can Eylea's Momentum Carry It?
  • 4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
    • 4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
    • 4.4.2 Judicial Review Averted in the UK by Price Adjustment
    • 4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
    • 4.4.4 Roche and Novartis Challenge CATT's Headline Conclusions
    • 4.4.5 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
    • 4.4.6 Avastin Revenue Forecast, 2019-2029
  • 4.4.7 Will Anything Dislodge Avastin from its Central Position?
  • 4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
    • 4.5.1 Visudyne Revenue Forecast, 2019-2029
  • 4.6 Other Drugs for Macular Degeneration and Other Retinal Diseases
    • 4.6.1 Other Drugs Revenue Forecast, 2019-2029

5. Pipeline for Wet AMD Segment

  • 5.1 The Leading Pipeline Candidates
  • 5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
    • 5.2.1 Three Phase III Trials to Confirm Fovista's Outstanding Phase II Results
    • 5.2.2 Ophthotech Goes Public to Fund Phase III Effort
    • 5.2.3 Ophthotech Partners with Novartis for Fovista
    • 5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
    • 5.2.5 The Move towards Combination Therapies
  • 5.3 Other Growth Factor Targets in the Pipeline
    • 5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
    • 5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
    • 5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
  • 5.4 APL-2: Evaluation for the treatment of patients with Geographic Atrophy (GA) related to AMD
    • 5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
    • 5.4.2 Binding Affinity Comparable to Eylea
  • 5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
    • 5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
    • 5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
    • 5.5.3 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
    • 5.5.4 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
    • 5.5.5 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
  • 5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
    • 5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
    • 5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
  • 5.7 Other Targets Under Investigation in wAMD Drug Development
    • 5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
    • 5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
    • 5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
    • 5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
    • 5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
    • 5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
    • 5.7.7 Novel Anti-Angiogenic Treatments in Development: Ora Bio's ORA102 and CoMentis' ATG003
    • 5.7.8 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
    • 5.7.9 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
  • 5.8 Regenerative Medicine Approaches
    • 5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
    • 5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
    • 5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes

6. Pipeline for Dry AMD Segment

  • 6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
  • 6.2 MC-1101 (MacuCLEAR): Leading the Pack?
    • 6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
    • 6.2.2 Novel Endpoints in Phase III Study
    • 6.2.3 Can MacuCLEAR Make It?
  • 6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase III
    • 6.3.1 Study Result Declared in May 2016
    • 6.3.2 Other Visual Cycle Modulators
  • 6.4 High Hopes for Complement Inhibition in Dry AMD
    • 6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
    • 6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
  • 6.5 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
    • 6.5.1 Iluvien (Alimera Sciences): Study terminated
    • 6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
  • 6.6 Neuroprotection: One of Modern Medicine's Holy Grails
    • 6.6.1 Tandospirone (Alcon): Not effective in GA
    • 6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
    • 6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
    • 6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
  • 6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
    • 6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
    • 6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
    • 6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
    • 6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
    • 6.7.5 First iPSC Trial in Japan in Dry AMD Patients
    • 6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
  • 6.8 Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment

  • 7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
  • 7.2 Lucentis: The Game Changer for DR?
  • 7.3 New Anti-VEGF Additions
    • 7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
  • 7.4 Steroids in Development for DR
    • 7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
    • 7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
    • 7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
    • 7.4.4 Cortiject (Santen): Prodrug Candidate
    • 7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
  • 7.5 Other Products in Development for DR
    • 7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
    • 7.5.2 Vitreosolve (Innovations in Sight): Will a Phase III Trial Be Initiated?
    • 7.5.3 TriLipix (Abbott): No New Development for Promising Drug
    • 7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013

8. Regional Market Breakdown, 2019-2029

  • 8.1 Which Markets Hold the Most Revenue Growth Potential?
  • 8.2 The US: Leading Market for Retinal Diseases
  • 8.3 Japan: Strong Market Potential
  • 8.4 EU5: Ageing Populations to Drive Market Growth
  • 8.5 BRIC Nations: The Biggest Growth Driver for the Market

9. Leading Companies in Global AMD and Other Retinal Diseases Market, 2018

  • 9.1 Novartis AG
    • 9.1.1 Company Overview
    • 9.1.2 Financials
    • 9.1.3 Key News
  • 9.2 F. Hoffmann-La Roche, Ltd.
    • 9.2.1 Company Overview
    • 9.2.2 Financials
    • 9.2.3 Key News
  • 9.3 Bayer AG
    • 9.3.1 Company Overview
    • 9.3.2 Financials
    • 9.3.3 Key News
  • 9.4 Regeneron Pharmaceuticals
    • 9.4.1 Company Overview
    • 9.4.2 Financials
    • 9.4.3 Key News
  • 9.5 Valent Pharmaceuticals International, Inc.
    • 9.5.1 Company Overview
    • 9.5.2 Financials
    • 9.5.3 Key News
  • 9.6 Pfizer Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Financials
    • 9.6.3 Key News
  • 9.7 Acucela, Inc.
    • 9.7.1 Company Overview
    • 9.7.2 Key News
  • 9.8 IVERIC bio, Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Financials
    • 9.8.3 Key News
  • 9.9 GlaxoSmithKline Pharmaceuticals Ltd.
    • 9.9.1 Company Overview
    • 9.9.2 Financials
  • 9.10 Allergan PLC
    • 9.10.1 Company Overview
    • 9.10.2 Financials

10. Qualitative Industry and Market Analysis

  • 10.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
  • 10.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
  • 10.3 Opportunities: New Markets and R&D Synergies
  • 10.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
  • 10.5 Social: Low Diagnosis, Low Compliance
  • 10.6 Technological: Innovation for the Eye
  • 10.7 Economic: Off-Label Treatment and Reimbursement Issues
  • 10.8 Political: The Demography and Diabetes Challenges

11. Conclusions

  • 11.1 The Age of Lucentis: Nearing Its Conclusion?
  • 11.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
  • 11.3 Indications Outside Wet AMD to Gain in Importance
  • 11.4 Dry AMD Market Has Huge Potential
  • 11.5 Fovista Most Prominent Among the Pipeline Candidates
  • 11.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 2.2 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 2.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2018
  • Table 3.1 Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2018
  • Table 3.2 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2018
  • Table 3.3 Global Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2023
  • Table 3.4 Global Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2029
  • Table 3.5 Global Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2023
  • Table 3.6 Global Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2029
  • Table 3.7 Global DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2023
  • Table 3.8 Global DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2023-2029
  • Table 3.9 Global Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 3.10 Global Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 3.11 Global Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2018, 2023 and 2029
  • Table 4.1 Global Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 4.2 Global Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 4.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2023
  • Table 4.4 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2029
  • Table 4.5 Lucentis: Revenue ($bn), AGR (%), 2014 & 2017
  • Table 4.6 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
  • Table 4.7 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 4.8 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 4.9 Eylea: U.S. Revenue ($bn), AGR (%), 2017-2018
  • Table 4.10 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 4.11 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 4.12 Avastin: Revenue ($bn), AGR (%), 2016-2018
  • Table 4.13 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 4.14 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 4.15 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 4.16 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 4.17 Other Drugs Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 4.18 Other Drugs Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 5.1 Selected R&D Pipeline for wAMD, 2018
  • Table 6.1 Selected R&D Pipeline for Dry AMD, 2018
  • Table 7.1 Selected R&D Pipeline for DR, 2017
  • Table 8.1 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.2 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 8.3 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.4 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 8.5 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.6 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 8.7 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.8 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 8.9 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2023
  • Table 8.10 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2023-2029
  • Table 9.1 Novartis AG: Overview 2018
  • Table 9.2 Novartis Revenue ($bn) 2016, 2017
  • Table 9.3 Roche: Overview 2018
  • Table 9.4 Roche Revenue ($bn) 2017, 2018
  • Table 9.5 Bayer: Overview 2018
  • Table 9.6 Bayer AG Revenue ($bn) 2017 and 2018
  • Table 9.7 Regeneron Pharmaceuticals: Overview 2017
  • Table 9.8 Regeneron Pharmaceuticals: Revenue ($bn) 2016 and 2017
  • Table 9.9: Valent Pharmaceuticals International Inc.: Overview 2018
  • Table 9.10 Valent Pharmaceuticals International Inc: Revenue ($bn) 2016 and 2017
  • Table 9.11: Pfizer Inc.: Overview 2018
  • Table 9.12 Pfizer Inc: Revenue ($bn) 2017, 2018
  • Table 9.13: Acucela Inc.: Overview 2018
  • Table 9.14: IVERIC bio, Inc.: Overview 2018
  • Table 9.15 IVERIC bio, Inc. ($bn) 2017, 2018
  • Table 9.16: GlaxoSmithKline Pharmaceuticals Ltd.: Overview 2018
  • Table 9.17 GlaxoSmithKline Pharmaceuticals Ltd ($bn) 2017, 2018
  • Table 9.18: Allergan PLC: Overview 2018
  • Table 9.19 Allergan PLC ($bn) 2017, 2018
  • Table 10.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2018
  • Table 10.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2018
  • Table 10.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis)

List of Figures

  • Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2018-2029
  • Figure 2.2 Market Breakdown by Product Revenue ($bn), Market Share (%), 2018
  • Figure 2.3 Market Breakdown by Company: Market Share (%), 2018
  • Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2018
  • Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2018
  • Figure 3.1 Market Breakdown by Disease Segment: Revenues ($bn), 2018
  • Figure 3.2 Market Breakdown by Disease Segment: Market Share (%), 2023
  • Figure 3.3 Global Wet AMD Segment Forecast: Revenue ($bn), 2019-2029
  • Figure 3.4 Global Dry AMD Segment Forecast: Revenue ($bn), 2019-2029
  • Figure 3.5 DR Segment Forecast: Revenue ($bn), 2019-2029
  • Figure 3.6 Global Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2019-2029
  • Figure 3.7 Global Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2018, 2023 and 2029
  • Figure 3.8 Market Breakdown by Disease Segment: Market Share (%), 2023
  • Figure 3.9 Market Breakdown by Disease Segment: Market Share (%), 2029
  • Figure 4.1 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2023
  • Figure 4.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2029
  • Figure 4.3 Market Forecast by Product: Revenue ($bn), 2019-2029
  • Figure 4.4 Market Breakdown by Product: Revenue ($bn), 2018, 2023 and 2029
  • Figure 4.5 Lucentis: Revenues Forecast ($bn), 2019-2029
  • Figure 4.6 Drivers and Restraints for Lucentis, 2018
  • Figure 4.7 Eylea Forecast: Revenue ($bn), 2018-2029
  • Figure 4.8 Drivers and Restraints for Eylea, 2018
  • Figure 4.9 Avastin Forecast: Revenue ($bn), 2019-2029
  • Figure 4.10 Drivers and Restraints for Avastin, 2018
  • Figure 4.11 Visudyne Forecast: Revenues ($bn), 2019-2029
  • Figure 4.12 Other Drugs Forecast: Revenues ($bn), 2019-2029
  • Figure 8.1 Regional Breakdown: Revenue ($bn), 2019-2029
  • Figure 8.2 Regional Breakdown: Revenue ($bn), 2018, 2023 and 2029
  • Figure 8.3 Regional Market Share (%), 2018
  • Figure 8.4 Regional Market Share (%), 2023
  • Figure 8.5 Regional Market Share (%), 2029
  • Figure 8.6 US Market: Revenue ($bn), 2019-2029
  • Figure 8.7 Japan: Revenue ($bn), 2019-2029
  • Figure 8.8 EU5: Grouped Revenue ($bn), 2019-2029
  • Figure 8.9 EU5 Breakdown Forecasts: Revenue ($bn), 2019-2029
  • Figure 8.10 EU5 Breakdown: Market Share (%), 2018
  • Figure 8.11 EU5 Breakdown: Market Share (%), 2023
  • Figure 8.12 EU5 Breakdown: Market Share (%), 2029
  • Figure 8.13 BRIC Nations Forecast: Revenue ($bn), 2019-2029
  • Figure 8.14 BRIC Nations Forecasts: Revenue ($bn), 2019-2029
  • Figure 8.15 Market Share (%) within BRIC Group by Country, 2018
  • Figure 8.16 Market Share (%) within BRIC Group by Country, 2023
  • Figure 8.17 Market Share (%) within BRIC Group by Country, 2029

COMPANIES LISTED:

  • Abbott
  • Acucela Pharmaceuticals
  • Alcon
  • Alimera Sciences
  • Allegro Opthalmics
  • Allergan
  • Ampio Pharmaceuticals
  • Ampio Pharmaceuticals
  • Avalanche Biotechnologies
  • Bayer Healthcare
  • Bioeq GmbH
  • Biophytis
  • Biovail Corporation
  • Bristol-Myers Squibb
  • CalTech
  • Cell Cure Neurosciences Ltd
  • Centocor
  • Chengdu Kanghong
  • Chengdu Kanghong Biotech
  • Clearside Biomedical
  • CoMentis
  • Daiichi Sankyo
  • Diffusion Pharmaceuticals
  • Eli Lilly
  • ESBATech
  • Eye Gate Pharmaceuticals
  • ForSight Vision4
  • Gene Signal
  • Genentech
  • GlaxoSmithKline
  • Hemera Biosciences
  • iCo Therapeutics
  • Icon Bioscience
  • Iconic Therapeutics
  • Janssen Pharmaceuticals
  • Jiangsu T-mab BioPharma
  • Kala Pharmaceuticals
  • LPATH
  • Lpath, Inc.
  • MacuCLEAR
  • Mateon Therapeutics
  • Medical Need
  • Merck Sharp & Dohme
  • Mesoblast
  • Mitsubishi Tanabe Pharma
  • Molecular Partners
  • MorphoSys
  • Neuron Systems
  • Neurotech
  • Novartis
  • Novo Nordisk
  • Oakwood Laboratories
  • Ocata Therapeutics (Advanced Cell Technology)
  • OHR Pharmaceutical
  • Ophthotech Corporation
  • OpRegen (Biotime)
  • Opthea
  • Ora Bio
  • Othera Pharmaceuticals
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Oxigene
  • PanOptica
  • Pfenex
  • Pfizer
  • pSivida
  • Quark
  • Regenerative Patch Technologies
  • Regeneron/Bayer
  • Regenxbio
  • ReVision Therapeutics
  • River Vision Development
  • Roche
  • RXi Pharmaceuticals
  • Sanofi
  • Santen Pharmaceutical
  • SARcode Bioscience
  • SciFluor Life Sciences
  • Senju Pharmaceutical
  • SGS Life Science Services
  • Stealth BioTherapeutics
  • StemCells
  • Stemedica Cell Technologies
  • SV Life Sciences
  • Third Rock Ventures
  • ThromboGenics
  • Tyrogenex
  • UCB
  • Valeant Pharmaceuticals
  • Vitreoretinal Technologies
  • Xcovery Vision

List of Organisations Mentioned in the Report:

  • Association for Research in Vision and Ophthalmology
  • Columbia University
  • Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • International Diabetes Federation
  • Italian Competition Authority (ICA)
  • Japanese Ministry of Health, Labour and Welfare
  • Macula and Retina Institute Glendale
  • NHS
  • NICE
  • Oregon Health and Science University
  • Retinal Research Institute
  • Riken Institute
  • UK's General Medical Council
  • University College London (UCL)
  • US National Eye Institute
  • World Health Organisation (WHO)